Correlation Between Precision BioSciences and Karyopharm Therapeutics

Can any of the company-specific risk be diversified away by investing in both Precision BioSciences and Karyopharm Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Precision BioSciences and Karyopharm Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Precision BioSciences and Karyopharm Therapeutics, you can compare the effects of market volatilities on Precision BioSciences and Karyopharm Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Precision BioSciences with a short position of Karyopharm Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Precision BioSciences and Karyopharm Therapeutics.

Diversification Opportunities for Precision BioSciences and Karyopharm Therapeutics

-0.45

Correlation Coefficient

Precision BioSciences  Karyopharm Therapeutics

Very good diversification

The 3 months correlation between Precision and Karyopharm is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Precision BioSciences and Karyopharm Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Karyopharm Therapeutics and Precision BioSciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Precision BioSciences are associated (or correlated) with Karyopharm Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Karyopharm Therapeutics has no effect on the direction of Precision BioSciences i.e., Precision BioSciences and Karyopharm Therapeutics go up and down completely randomly.

Pair Corralation between Precision BioSciences and Karyopharm Therapeutics

Given the investment horizon of 90 days Precision BioSciences is expected to under-perform the Karyopharm Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Precision BioSciences is 1.19 times less risky than Karyopharm Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Karyopharm Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  343.00  in Karyopharm Therapeutics on September 4, 2024 and sell it today you would lose (262.00) from holding Karyopharm Therapeutics or give up 76.38% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Precision BioSciences  vs.  Karyopharm Therapeutics

Precision BioSciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Precision BioSciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's forward indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Karyopharm Therapeutics

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Karyopharm Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Karyopharm Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Precision BioSciences and Karyopharm Therapeutics

The main advantage of trading using opposite Precision BioSciences and Karyopharm Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Precision BioSciences position performs unexpectedly, Karyopharm Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Karyopharm Therapeutics will offset losses from the drop in Karyopharm Therapeutics' long position.

The idea behind Precision BioSciences and Karyopharm Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.